- Home
- ABBV vs AZN Comparison
ABBV vs AZN Comparison
Compare ABBV & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ABBV | AZN |
|---|---|---|
| Founded | 2012 | 1992 |
| Country | United States | United Kingdom |
| Employees | N/A | 96100 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 358.5B | 316.4B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | ABBV | AZN |
|---|---|---|
| Price | $200.90 | $182.64 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 18 | 1 |
| Target Price | ★ $253.71 | N/A |
| AVG Volume (30 Days) | ★ 4.8M | 1.8M |
| Earning Date | 04-29-2026 | 04-29-2026 |
| Dividend Yield | ★ 3.39% | 1.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $61,160,000,000.00 | N/A |
| Revenue This Year | $11.87 | $10.34 |
| Revenue Next Year | $8.12 | $6.43 |
| P/E Ratio | $85.67 | ★ $31.91 |
| Revenue Growth | ★ 8.57 | N/A |
| 52 Week Low | $180.25 | $66.16 |
| 52 Week High | $244.81 | $212.71 |
Technical Indicators
Market Signals| Indicator | ABBV | AZN |
|---|---|---|
| Relative Strength Index (RSI) | 42.15 | 37.94 |
| Support Level | $189.19 | $182.39 |
| Resistance Level | $234.76 | $208.61 |
| Average True Range (ATR) | 5.00 | 2.96 |
| MACD | 0.37 | -1.28 |
| Stochastic Oscillator | 42.41 | 14.40 |
Price Performance
Historical ComparisonAbout ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (over 40% of total revenue), cardiovascular, renal, and metabolic (over 20%), rare disease (16%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one-third of its sales.